• 1
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 733.
  • 2
    Mettlin C. The American Cancer Society National Prostate Cancer Detection Project and national patterns of prostate cancer detection and treatment. CA Cancer J Clin 1997; 47: 26572.
  • 3
    Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159: 35764.
  • 4
    Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992; 70: 31123.
  • 5
    Zincke H. The role of pathologic variables and hormonal treatment after radical prostatectomy for stage D1 disease. Oncology 1991; 5: 12942.
  • 6
    Zincke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989; 33: 2736.
  • 7
    Cheng CW, Bergstralh EJ, Zincke H. Stage D1 prostate cancer: a nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer 1993; 71: 9961004.
  • 8
    Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998; 22: 1491500.
  • 9
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymph adenectomy in men with node positive prostate cancer. N Engl J Med 1999; 341: 17818.
  • 10
    Zincke H. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for stage C or D1 adenocarcinoma of the prostate: possible beneficial effect of adjuvant treatment. Bethesda, MD: NCI Monographs, 1988: 10915.
  • 11
    Golimbu M, Provet J, Al-Askari S, Morales P. Radical prostatectomy for stage D1 prostate cancer: prognostic variable and results of treatment. Urology 1987; 30: 42735.
  • 12
    DeKernion JB, Huang M-Y, Kaufman JJ, Smith RB. Result of treatment of patients with stage D1 prostatic carcinoma. Urology 1985; 26: 44651.
  • 13
    Stein A, DeKernion JB. Adjuvant endocrine therapy after radical prostatectomy for stage D1 prostate carcinoma. Semin Urol 1990; 8: 184.
  • 14
    DeKernion JB, Neuwirth H, Stein A, Dorey F, Stenzi A, Hannah J, et al. Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 1990; 144: 7003.
  • 15
    Austenfeld MS, Davis BE. New concepts in the treatment of stage D1 adenocarcinoma of the prostate. Urol Clin North Am 1990; 17: 86784.
  • 16
    Frohmuller HGW, Theiss M, Manseck A, Wirth MP. Survival and quality of life of patients with stage D1 (T1–3, pN 1–2 m0) prostate cancer. Eur Urol 1995; 27: 2026.
  • 17
    Hanks GE. The challenge of treating node-positive prostate cancer: an approach to resolving the questions. Cancer 1993; 71: 10148.
  • 18
    Seay TM, Blute MC, Zincke H. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate. Urology 1997; 50: 8337.
  • 19
    Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. AJCC cancer staging manual. Philadelphia: Raven and Lippincott, 1997.
  • 20
    Bostwick DG. Neoplasms of the prostate. In: BostwickDG, EbleJN, editors. Urologic surgical pathology, edition 1. St. Louis: Mosby, 1997: 343422.
  • 21
    Bostwick DG. Grading prostate cancer. Am J Clin Pathol 1994; 102: S3856.
  • 22
    Bundrick WS, Culkin DJ, Mata JA, Zitman RI, Venable DD. Evaluation of the current incidence of nodal metastasis from prostate cancer. J Surg Oncol 1993; 52: 26971.
  • 23
    Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997; 278: 4450.
  • 24
    Mettli CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996; 77: 21626.
  • 25
    Zincke H, Utz DC, Thule PM, Taylor WF. Treatment options for patients with stage D1 (T0–3, N1–2, M0) adenocarcinoma of prostate. Urology 1987; 30: 30715.
  • 26
    Zincke H. Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Semin Urol 1990; 8: 17583.
  • 27
    Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999; 161: 12238.
  • 28
    Zincke H, Utz DC, Myers RP, Farrow GM, Patterson DE, Furlow WL. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement. Urology 1982; 19: 23847.
  • 29
    Cadeddu JA, Partin AW, Epstein JI, Walsh PC. Stage D1 (T1–3, N1–3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997; 50: 2515.
  • 30
    Frazier HA, Robertson JE, Paulson DF. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J Urol 1994; 12: 30812.
  • 31
    Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 1994; 152: 1077081.
  • 32
    Steinberg GD, Epstein JI, Paintadosi S, Walsh PC. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974–1987. J Urol 1990; 144: 142532.
  • 33
    van den Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, Ten Kate FJW, et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. J Urol 1993; 150: 4006.
  • 34
    Davidson PJT, Hop W, Hurth KH, Fossa SD, Waehre H, Schroder FH, et al. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 to 4, N1 to 3, M0, D1). J Urol 1995; 154: 211822.
  • 35
    Smith JA Jr. , Middleton RG. Implications of volume of nodal metastasis inpatients with adenocarcinoma of the prostate. J Urol 1985;133: 6179.
  • 36
    Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr. , et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142: 3326.
  • 37
    Ferrari AC, Stone NN, Eyler JN. Prospective analysis of prostate-specific markers in pelvic lymph node of patients with high-risk prostate cancer. J Natl Cancer Inst 1997; 89: 1498504.
  • 38
    Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin of multiple foci of prostate intraepithelial neoplasia (PIN): comparison with matched foci of prostate cancer. Cancer 1998; 83: 199952002.
  • 39
    Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995; 55(22): 540814.
  • 40
    Cheng L, Bostwick DG, Li G, Wang Q, Hu N, Vortmeyer AO, et al. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 1999; 85: 201722.
  • 41
    Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of independent origin of multiple tumors from prostate cancer patients. J Natl Cancer Inst 1997; 90: 2337.
  • 42
    Cheng L, Leibovich BC, Bergstralh EJ, Scherer BG, Pacelli A, Ramnani DM, et al. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer 1999; 85: 24559.
  • 43
    Cheng L, Bergstralh EJ, Slezak J, Cheville JC, Zincke H, Bostwick DG. Dedifferentiation in metastatic progression of prostate cancer. Cancer 1999; 86: 65763.
  • 44
    Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver A, et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res 1999; 5: 28203.
  • 45
    Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 1996; 88: 77981.
  • 46
    Schellhammer P, Cockett A, Boccon-Gibod L, Gospodarowicz M, Krongrad A, Thompson IM, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology 1997; 49: 2738.
  • 47
    Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment of disease outcome. Urology 1993; 42: 283.